FDA Supports Advancement of GENV-HEM Gene Therapy for Hemophilia A
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA is supporting the advancement of a gene therapy for hemophilia A. This development is occurring in a market where other treatments, such as Roche's HEMLIBRA, have reportedly seen significant uptake. The relationship between the FDA's support for the gene therapy and the existing market for hemophilia A treatments is unclear.